B Cell Acute Lymphoblastic Leukemia clinical trials

Explore recruiting b cell acute lymphoblastic leukemia clinical trials.

Recruiting b cell acute lymphoblastic leukemia studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

B Cell Acute Lymphoblastic Leukemia trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

Application of antiCD19 CAR T lymphocytes for the treatment of adult patients with B-cell acute lymphoblastic leukemia with resistance, relapse or detectable measurable residual disease. Phase I/II clinical trial (MERMAID1)

Poland

Phase I and Phase II (Integrated)- First administration to humans EU CTIS Study details

A Phase 2/3, Randomized, Open-Label, Comparison Study of MK-1045 Versus Blinatumomab in Participants With Relapsed or Refractory CD19+ B-Cell Acute Lymphoblastic Leukemia (B-ALL)

Greece, Netherlands, Sweden, France, Italy, Spain +1 more

Phase II and Phase III (Integrated) EU CTIS Study details

The INFLUENCE Trial: Improving EveNt Free Survival by Optimizing FLUdarabine Exposure during LymphodepletioN for CAR T CEll Therapy: a randomized, multi-center study of children and young adults with B-cell acute lymphoblastic leukemia

Spain, Germany, Netherlands

Therapeutic confirmatory (Phase III) EU CTIS Study details

Open label dose-escalation and dose-expansion study to evaluate the safety, expansion, persistence and clinical activity of UCART22 (allogeneic engineered T-cells expressing Anti-CD22 Chimeric Antigen Receptor) in patients with relapsed or refractory CD22+ B-cell Acute Lymphoblastic Leukemia (B-ALL)

France, Italy, Spain

Phase I and Phase II (Integrated)- First administration to humans EU CTIS Study details

A modular Phase I/II, open-label, multi-center study to evaluate the safety, tolerability, pharmacokinetics, immunogenicity, and preliminary efficacy of AZD4512 monotherapy or in combination with anticancer agent(s) in participants with Acute Lymphoblastic Leukemia

Spain

Phase I and Phase II (Integrated)- First administration to humans EU CTIS Study details

Phase I clinical trial on the use of fresh, allogeneic, second-generation CD19-CAR T cells for treatment of children and young adult with relapsed/refractory B-cell Acute Lymphoblastic Leukemia

Italy

Human Pharmacology (Phase I)- First administration to humans EU CTIS Study details

B Cell Acute Lymphoblastic Leukemia trials by city

B Cell Acute Lymphoblastic Leukemia in Toronto B Cell Acute Lymphoblastic Leukemia in Vancouver B Cell Acute Lymphoblastic Leukemia in Montreal B Cell Acute Lymphoblastic Leukemia in Calgary B Cell Acute Lymphoblastic Leukemia in Edmonton B Cell Acute Lymphoblastic Leukemia in Ottawa B Cell Acute Lymphoblastic Leukemia in Winnipeg B Cell Acute Lymphoblastic Leukemia in Quebec City B Cell Acute Lymphoblastic Leukemia in Hamilton B Cell Acute Lymphoblastic Leukemia in Kitchener B Cell Acute Lymphoblastic Leukemia in London B Cell Acute Lymphoblastic Leukemia in Halifax B Cell Acute Lymphoblastic Leukemia in New York B Cell Acute Lymphoblastic Leukemia in Los Angeles B Cell Acute Lymphoblastic Leukemia in Chicago B Cell Acute Lymphoblastic Leukemia in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease